<DOC>
	<DOCNO>NCT01166178</DOCNO>
	<brief_summary>This study design evaluate efficacy safety zoledronic acid 5 mg intravenous ( i.v . ) relative placebo Multiple Sclerosis ( MS ) patient osteoporosis support optimal use zoledronic acid indication . Primary objective change Bone Mineral Density ( BMD ) lumbar spine ( L1-L4 ) total hip region assess T-Score month 12 relative screening measure Dual X-ray Absorptiometry ( DXA ) . This double-blind period follow 52-week open-label treatment phase assess long-term efficacy safety zoledronic acid patient .</brief_summary>
	<brief_title>Zoledronic Acid MS-patients With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion : Written inform consent participate trial Definite diagnosis Multiple Sclerosis ( MS ) define 2005 revise McDonald criterion MSsubtype : Relapsingremitting MS ( RRMS ) , Secondary progressive MS ( SPMS ) , Primary progressive MS ( PPMS ) Expanded Disability Status Scale ( Kurtzke 's scale ; EDSS ) score 2.5 6.5 ( include ) Bone mineral density ( BMD ) Tscore le equal 2.0 equal 4.0 lumbar spine ( L1L4 least 2 evaluable vertebra ) and/or total hip region and/or femoral neck recent Dual XRay Absorptiometry ( DXA ) scan ( &lt; = 3 month ) Sufficient ability read , write communicate comprehensibly comply study procedures No immunomodulatory treatment MS within last 30 day stable well tolerated therapy betainterferon formulation , glatirameracetate fingolimod least 30 day immediately prior baseline Exclusion criterion : Contraindications Calcium Vitamin D zoledronic acid accord summary product characteristic More one osteoporotic fracture Concomitant medication influence bone mineral density ( eg . enzyme induce antiepileptic like Carbamazepin , Phenytoin , Phenobarbital , Primidon ) Any neurological disorder MS know affect bone mineral density ( e.g . muscular dystrophy , severe paresis reason MS , degenerative nervous disorder , stroke ) Women pregnant breast feeding , menstruate capable become pregnant . Baseline renal insufficiency 25OH vitamin D level &lt; 10 ng/ml screen Serum calcium level &gt; 2.75 mmol/l ( 11.0 mg/dL ) &lt; 2.00 mmol/L ( 8.0 mg/dL ) screen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Zoledronic Acid</keyword>
</DOC>